课题基金 / 基金详情

TEMOZOLOMIDE (SCH52365) IN PATIENTS W/ ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE

TEMOZOLOMIDE (SCH52365) IN PATIENTS W/ ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE
替莫唑胺 (SCH52365) 用于首次复发的间变性星形细胞瘤患者
批准号：
6244603
负责人：
HARRY S GREENBERG
金额：
$2.22万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-20 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244603
关键词：
antineoplastics clinical research drug adverse effect drug screening /evaluation glioblastoma multiforme human mortality human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer relapse /recurrence quality of life

项目摘要

项目成果

HARRY S GREENBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a phase II study of temozolomide (SCH 52365) in the treatment of patients with anaplastic astrocytoma at first relapse. The efficacy will be measured as progression free survival rate at six months. Secondary measures efficacy will be quality of life and survival. Toxicity will be carefully monitored.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS
TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS
海外基金